Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832477 · ClinicalTrials.gov registry record · NA
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
A NA study of Substance Use and Stigma, Social, sponsored by University of Connecticut.
- Active
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT04832477: Active NA study of Substance Use and Stigma, Social, sponsored by University of Connecticut.
NCT04832477 is a NA study of Substance Use and Stigma, Social that is active but no longer recruiting, run by University of Connecticut. The registered enrollment target is 500 participants, below the 1,255-participant average among 88 other Substance Use trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832477, a NA study of Substance Use and Stigma, Social, is active but no longer recruiting, sponsored by University of Connecticut.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research aims to assess the multiple forms and paths of stigma and substance use as they relate to pre-exposure prophylaxis (PrEP) use for HIV prevention. How stigma and an evolving public health landscape impact PrEP use among Black sexual minorit men who use substances is unknown. The current application focuses on addressing critical and novel questions to improving the essential building blocks of biomedical prevention approaches by providing crucial information for enhancing interventions to lower HIV prevalence among substance using Black sexual minority men.
Primary Outcome
TFV-DP (Tenofovir Diphosphate) biological testing for PrEP pill taking will be assessed. TFV-DP measured at \>700 fmol will be interpreted as having taken ≥4 doses/week, and TFV-DP measured at \>700 fmol over two consecutive time points will be interpreted as persistence to taking PrEP. The lower scale limit is 0 and upper scale limit is approximately around 2500. Higher values indicate greater medication adherence to PrEP pills.
Conditions Studied
Interventions
- BEHAVIORAL Stigma counseling for PrEP use
Study Locations (1)
Georgia
- SHARE Project - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2026-02-04 |
| Phase | NA |
What the registry record for NCT04832477 still lists
NCT04832477 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,255-participant average among 88 other Substance Use trials with a reported enrollment target (60% lower).
The record links to 4 conditions, with Substance Use appearing as the primary indexed condition, and to 1 intervention - of which Stigma counseling for PrEP use is the first listed.
NCT04832477 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04832477 about?
NCT04832477 is a clinical study titled "Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US". The proposed research aims to assess the multiple forms and paths of stigma and substance use as they relate to pre-exposure prophylaxis (PrEP) use for HIV prevention. How stigma and an evolving public health landscape impact PrEP use among Black sexual minorit men who use substances is unknown. The...
What is the current status of trial NCT04832477?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2021-09-15. Estimated completion is 2026-02-04.
What conditions does trial NCT04832477 study?
This clinical trial studies the following conditions: Substance Use, Stigma, Social, STI, HIV Seropositivity.
What interventions are being tested in trial NCT04832477?
The interventions under investigation include: Stigma counseling for PrEP use (BEHAVIORAL).
Who is sponsoring clinical trial NCT04832477?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04832477 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04832477's enrollment target sits among peer trials
500 19th of 88 higher than 70 of 88 other Substance Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Native Spirit: Significant Aim 3: Intervention
RECRUITING · NA
-
Parent SMART (Substance Misuse in Adolescents in Residential Treatment)
RECRUITING · NA
-
Cultural Adaptation of Drug Treatment for DJJ Youth
RECRUITING · NA
-
Adaptation and Evaluation of Bright Horizons
RECRUITING · NA
-
Teen Health Choices & Wellness
RECRUITING · NA
-
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI